Author: Izquierdo, Laure; Oliveira, Catarina; Fournier, Carole; Descamps, Véronique; Morel, Virginie; Dubuisson, Jean; Brochot, Etienne; Francois, Catherine; Castelain, Sandrine; Duverlie, Gilles; Helle, Francois
Title: Hepatitis C Virus Resistance to Carbohydrate-Binding Agents Document date: 2016_2_12
ID: 1a4l1beo_7
Snippet: ConA and GNA were purchased from Sigma. Purified CV-N was kindly provided by K. Gustafson (National Institutes of Health, National Cancer Institute, Frederick, MD, USA). GRFT was kindly provided by K. E. Palmer (Owensboro Cancer Research Program, Owensboro, Kentucky, USA). The soluble recombinant form of the CD81 large extracellular loop (CD81-LEL) was produced as a glutathione S-transferase fusion protein as described previously [20] . The 3/ 11.....
Document: ConA and GNA were purchased from Sigma. Purified CV-N was kindly provided by K. Gustafson (National Institutes of Health, National Cancer Institute, Frederick, MD, USA). GRFT was kindly provided by K. E. Palmer (Owensboro Cancer Research Program, Owensboro, Kentucky, USA). The soluble recombinant form of the CD81 large extracellular loop (CD81-LEL) was produced as a glutathione S-transferase fusion protein as described previously [20] . The 3/ 11 monoclonal antibody (MAb) (anti-E2; kindly provided by J. McKeating, University of Birmingham, United Kingdom) [21] and A4 MAb (anti-E1) [22] , were produced in vitro by using a MiniPerm apparatus (Heraeus), as recommended by the manufacturer. For neutralization assays, the 3/11 MAb was purified using the Pierce Protein G plus Agarose, as recommended by the manufacturer (Pierce). The C4 MAb (anti-actin) was purchased from Millipore.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date